rs771350413
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_183075.3(CYP2U1):c.1033A>G(p.Ile345Val) variant causes a missense change. The variant allele was found at a frequency of 0.0000372 in 1,613,898 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_183075.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CYP2U1 | NM_183075.3 | c.1033A>G | p.Ile345Val | missense_variant | Exon 2 of 5 | ENST00000332884.11 | NP_898898.1 | |
CYP2U1 | XM_005262717.2 | c.1087A>G | p.Ile363Val | missense_variant | Exon 2 of 5 | XP_005262774.1 | ||
CYP2U1 | XM_005262720.2 | c.491-1864A>G | intron_variant | Intron 1 of 3 | XP_005262777.1 | |||
LOC107986298 | XR_001741784.2 | n.204+33208T>C | intron_variant | Intron 1 of 1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152218Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.0000200 AC: 5AN: 250150Hom.: 0 AF XY: 0.0000296 AC XY: 4AN XY: 135236
GnomAD4 exome AF: 0.0000397 AC: 58AN: 1461680Hom.: 0 Cov.: 32 AF XY: 0.0000399 AC XY: 29AN XY: 727122
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152218Hom.: 0 Cov.: 31 AF XY: 0.0000134 AC XY: 1AN XY: 74360
ClinVar
Submissions by phenotype
Spastic paraplegia Uncertain:1
In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with CYP2U1-related disease. This variant is present in population databases (rs771350413, ExAC 0.005%). This sequence change replaces isoleucine with valine at codon 345 of the CYP2U1 protein (p.Ile345Val). The isoleucine residue is highly conserved and there is a small physicochemical difference between isoleucine and valine. -
Inborn genetic diseases Uncertain:1
The c.1033A>G (p.I345V) alteration is located in exon 2 (coding exon 2) of the CYP2U1 gene. This alteration results from a A to G substitution at nucleotide position 1033, causing the isoleucine (I) at amino acid position 345 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at